Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck organon & Co. — Total Revenues ($M) ($M)
Organon & Co. SEC Filings (NYSE: OGN, CIK 0001821825, spun off June 2, 2021)
Latest, FY2025
6,216
Period ended Dec 31, 2025
Change on a year earlier
-2.9%
6,403 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Organon & Co. — Total Revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,216 | -2.9% | Organon & Co. SEC Filing (0001628280-26-011125) ↗ |
| FY2024 | Dec 31, 2024 | 6,403 | +2.2% | Organon & Co. SEC Filing (0001628280-26-011125) ↗ |
| FY2023 | Dec 31, 2023 | 6,263 | +1.4% | Organon & Co. SEC Filing (0001628280-26-011125) ↗ |
| FY2022 | Dec 31, 2022 | 6,174 | -2.1% | Organon & Co. SEC Filing (0001821825-25-000006) ↗ |
| FY2021 | Dec 31, 2021 | 6,304 | -3.5% | Organon & Co. SEC Filing (0001628280-24-006733) ↗ |
| FY2020 | Dec 31, 2020 | 6,532 | -16.0% | Organon & Co. SEC Filing (0001821825-23-000003) ↗ |
| FY2019 | Dec 31, 2019 | 7,777 | – | Organon & Co. SEC Filing (0001821825-22-000002) ↗ |
Breakdown
What makes up organon & co. — total revenues ($m)
- Organon & Co. — Revenues from Related Party (Merck & Co., Inc. Transition/Supply) ($M)69,000,000 · FY2025
- Merck & Co., Inc. — Related-Party Sales to Organon ($M)383 · FY2022
- Merck & Co., Inc. — Related-Party Cost of Sales to Organon ($M)404 · FY2022
- Organon Revenue — United States ($M)1,604,000,000 · FY2025
- Organon Revenue — Total International ($M)4,612,000,000 · FY2025
- Organon Revenue — Europe and Canada ($M)1,618,000,000 · FY2025
- Organon Revenue — Asia Pacific and Japan ($M)1,000,000,000 · FY2025
- Organon Revenue — China ($M)829,000,000 · FY2025
- Organon Revenue — Latin America, Middle East, Russia and Africa (LAMERA) ($M)1,072,000,000 · FY2025
- Organon Revenue — Other ($M)93,000,000 · FY2025
- Organon & Co. — Gross Profit ($M)3,313 · FY2025
- Organon & Co. — Cost of Sales ($M)2,903 · FY2025
- Organon & Co. — Selling, General and Administrative (SG&A) ($M)1,721 · FY2025
- Organon & Co. — Research and Development (R&D) ($M)443 · FY2021
- Organon & Co. — Restructuring Charges ($M)95 · FY2025
- Organon & Co. — Net Income ($M)187 · FY2025
- Organon & Co. — Diluted EPS ($)0.72 · FY2025
- Organon & Co. — Operating Cash Flow ($M)700 · FY2025
- Organon & Co. — Capital Expenditures ($M)162 · FY2025
- Organon & Co. — Cash and Cash Equivalents ($M)574 · FY2025
- Organon & Co. — Inventories ($M)1,406 · FY2025
- Organon & Co. — Total Assets ($M)12,867 · FY2025
- Organon & Co. — Long-Term Debt ($M)8,628 · FY2025
Cite this data
StockData. (2026). Merck Organon & Co. — Total Revenues ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn_rev_tot
See every metric in the Merck KPI table. Data updated Oct 26, 2026.